Beam Therapeutics Inc Cash Flow Conversion Efficiency
Beam Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-66.10 Million) by net assets ($1.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Beam Therapeutics Inc for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Beam Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025. This chart illustrates how Beam Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BEAM stock price and chart for real-time trading data and today's change.
Beam Therapeutics Inc Cash Flow Conversion Ratio Explained
Beam Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Beam Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beam Therapeutics Inc ranked by their cash flow conversion efficiency. Review Beam Therapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Talos Energy
NYSE:TALO
|
0.148x |
|
Workiva Inc
NYSE:WK
|
-2.099x |
|
Thanachart Capital Public Company Limited
BK:TCAP
|
0.015x |
|
Graphic Packaging Holding Company
NYSE:GPK
|
-0.035x |
|
Shurgard Self Storage SA
BR:SHUR
|
0.020x |
|
Ruentex Development Co Ltd
TW:9945
|
0.017x |
|
Comet Holding AG
SW:COTN
|
0.119x |
|
Benchmark Electronics Inc
NYSE:BHE
|
0.031x |
Annual Cash Flow Conversion Efficiency for Beam Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025. Also see BEAM asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.24 Billion | $-345.10 Million | -0.279x | +41.13% |
| 2024-12-31 | $733.54 Million | $-347.25 Million | -0.473x | -211.37% |
| 2023-12-31 | $981.33 Million | $-149.19 Million | -0.152x | -595.02% |
| 2022-12-31 | $733.47 Million | $22.53 Million | 0.031x | +138.32% |
| 2021-12-31 | $826.74 Million | $-66.27 Million | -0.080x | +79.44% |
| 2020-12-31 | $245.56 Million | $-95.74 Million | -0.390x | +45.34% |
| 2019-12-31 | $100.94 Million | $-72.00 Million | -0.713x | -370.99% |
| 2018-12-31 | $134.03 Million | $-20.30 Million | -0.151x | -123.40% |
| 2017-12-31 | $-4.18 Million | $-2.71 Million | 0.647x | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more